Abstract
Objective Diagnosing acute pulmonary embolism (PE) is challenging because of nonspecific clinical symptoms. Soluble lectin-type oxidized low-density lipoprotein receptor (sLOX-1) has differential expression in arterial and venous disease. This study aimed to evaluate the relevance of soluble lectin-type oxidized low-density lipoprotein receptor (sLOX-1) as a diagnostic biomarker for acute PE.
Methods This observational study was performed at Beijing Anzhen Hospital in China. Patients with PE, aortic dissection (AD), myocardial infarction (MI) and healthy controls were enrolled in this cross-sectional study (n=90 each). Moreover, 730 patients with suspected PE were enrolled in this prospective study. The diagnostic performance of sLOX-1 was assessed using the receiver operating characteristic curve analysis.
Results In the development set, sLOX-1 levels were significantly lower in patients with PE than in those with AD, MI, or healthy controls. In the validation cohort, the area under the curve (AUC) of sLOX-1 for patients with PE from other chest pain diseases, particularly from AD was significantly higher than that of D-dimer (ΔAUC=0.32; 95%CI, 0.26-0.37; P<0.0001) with 77.0% specificity and 74.5% positive predictive value at the threshold of 600 pg/mL derived from the development set. By integrating sLOX-1 into existing diagnosis strategy (Wells rules combined D-dimer), the number of patients who were further categorized as workup for PE decreased from 417 to 209, with the positive detection rate of computed tomographic pulmonary angiography increased from 35.1% to 67.0%. Six patients with PE were missed in 208 excluded patients at a failure rate of 2.88%.
Conclusions Plasma sLOX-1 is a novel diagnostic tool that can rapidly categorize suspected PE as a workup for PE based on existing diagnostic strategy.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials, NCT04118634
Funding Statement
This study was supported by grants from the National Nature Science Foundation of China (82230013, 82241206).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Beijing Anzhen Hospital (No. 2018048X)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data referred to in the manuscript is availability.
